Should the term 'antipsychotic' be changed to 'multidimensional stabiliser' in bipolar disorder? Towards a new denomination for 'atypical antipsychotics'

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 8, 2013, Pages 707-709

  Altamura, Alfredo Carlo ^a   Dragogna, Filippo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; DEPRESSION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HOSPITAL SERVICE; HUMAN; HYPOMANIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MENTAL PATIENT; MONOTHERAPY; NOTE; PRACTICE GUIDELINE; PROPHYLAXIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; TERMINOLOGY AS TOPIC;

EID: 84884273061     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867413492572     Document Type: Note

References (24)

1. Ahlfors UG, Baastrup PC, Dencker SJ. Flupenthixol decanoate in recurrent manic depressive illness: A comparison with lithium. Acta Psychiatrica Scandinavica. 1981 ; 64: 226-237
2. Altamura AC. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: Are they 'stabiliser' rather than typical compounds?. International Clinical Psychopharmacology. 1996 ; 11: 153-155
3. Altamura AC. From 'classical' antipsychotics to 'multidimensional stabilisers': Do we need a new classification for novel drugs used in schizophrenia?. Neuropsychiatry. 2011 ; 1: 541-552
4. Altamura AC, Lietti L, Dobrea C, et al. Mood stabilisers for patients with bipolar disorder: The state of the art. Expert Review of Neurotherapeutics. 2011 ; 11: 85-99
5. Altamura AC, Moliterno D, Paletta S, et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: A prospective observational study. Clinical Drug Investigation. 2012 ; 1: 213-219
6. Altamura AC, Mundo E, Dell'Osso B, et al. Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: a 4-year follow-up naturalistic study. Journal of Affective Disorders. 2008 ; 110: 135-141
7. Altamura AC, Serati M, Buoli M, et al. Augmentative quetiapine in partial/non responders with generalized anxiety disorder: a randomized, placebo-controlled study. International Clinical Psychopharmacology. 2011 ; 26: 201-205
8. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. Journal of Affective Disorders. 2013 ; 145: 62-69
9. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet. 2011 ; 8: 1306-1315
10. Citrome L. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. Expert Review of Neurotherapeutics. 2010 ; 10: 1031-1037
11. Dunner DL. Atypical antipsychotics: Efficacy across bipolar disorder subpopulations. Journal of Clinical Psychiatry. 2005 ; 66: 20-27
12. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. Journal of Clinical Psychiatry. 1996 ; 57: 49-52
13. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: A Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. Journal of Clinical Psychiatry. 2010 ; 71: 372-380
14. Keating GM, Robinson DM. Quetiapine: A review of its use in the treatment of bipolar depression. Drugs. 2007 ; 67: 1077-1095
15. McIntyre RS. Acute treatment of patients with bipolar mixed episodes. Journal of Clinical Psychiatry. 2008 ; 69: e10
16. Malhi GS, Chengappa KN, Gershon S, et al. Atypical mood stabilisers: A new role for neuroleptics?. Bipolar Disorders. 2011 ; 13: 583-586
17. Mundo E, Cattaneo E, Russo M, et al. Clinical variables related to antidepressant-induced mania in bipolar disorder. Journal of Affective Disorders. 2006 ; 92: 227-230
18. Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biological Psychiatry. 2010 ; 68: 156-162
19. Ravindran AV, Al-Subaie A, Abraham G. Quetiapine: Novel uses in the treatment of depressive and anxiety disorders. Expert Opinion on Investigational Drugs. 2010 ; 19: 1187-1204
20. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabiliser with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. American Journal of Psychiatry. 2002 ; 159: 1146-1154
21. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine. 2007 ; 356: 1711-1722
22. Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: Results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). American Journal of Psychiatry. 2009 ; 166: 476-488
23. Szegedi A, Zhao J, van Willigenburg A, et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 2011 ; 11: 101
24. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disorders. 2009 ; 11: 225-255